特刊编辑寄语——“药物早期发现：进展与挑战”
Editorial for Special Issue-"Early-Stage Drug Discovery: Advances and Challenges".
机构信息
Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Kurt-Mothes-Str. 3, 06122 Halle, Germany.
出版信息
Int J Mol Sci. 2023 Mar 30;24(7):6516. doi: 10.3390/ijms24076516.
Abstract
The development of a new drug from the first hit to the launch of an approved product is a complex process that usually take around 12-15 years and costs more than USD 1-2 billion [...].
摘要
从第一个发现到批准上市的新药研发是一个复杂的过程，通常需要 12-15 年，花费超过 10-20 亿美元。
相似文献
1
Editorial for Special Issue-"Early-Stage Drug Discovery: Advances and Challenges".特刊编辑寄语——“药物早期发现：进展与挑战”
Int J Mol Sci. 2023 Mar 30;24(7):6516. doi: 10.3390/ijms24076516.
2
Principles of early drug discovery.早期药物发现的原则。
Br J Pharmacol. 2011 Mar;162(6):1239-49. doi: 10.1111/j.1476-5381.2010.01127.x.
3
Advancing Drug Discovery via Artificial Intelligence.人工智能推动药物发现。
Trends Pharmacol Sci. 2019 Aug;40(8):592-604. doi: 10.1016/j.tips.2019.06.004. Epub 2019 Jul 15.
4
The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization.计算机辅助药物发现工具包：在先导化合物发现和优化中的应用。
Curr Med Chem. 2019;26(21):3838-3873. doi: 10.2174/0929867324666171107101035.
5
In silico methods and tools for drug discovery.基于计算机的药物研发方法和工具。
Comput Biol Med. 2021 Oct;137:104851. doi: 10.1016/j.compbiomed.2021.104851. Epub 2021 Sep 8.
6
Recent Advances in Kinase Drug Discovery Part I: The Editors' Take.激酶药物研发新进展 第一部分：编辑视角。
Int J Mol Sci. 2021 Jul 15;22(14):7560. doi: 10.3390/ijms22147560.
7
Microfluidics contribution to pharmaceutical sciences: From drug discovery to post marketing product management.微流控技术在制药科学中的贡献：从药物发现到上市后产品管理。
J Pharm Biomed Anal. 2018 Sep 10;159:348-362. doi: 10.1016/j.jpba.2018.07.011. Epub 2018 Jul 11.
8
In silico pharmacology for a multidisciplinary drug discovery process.用于多学科药物发现过程的计算机模拟药理学
Drug Metabol Drug Interact. 2012;27(4):199-207. doi: 10.1515/dmdi-2012-0021.
9
Editorial to the Special Issue-"Natural Products and Drug Discovery".特刊编辑寄语——“天然产物与药物发现”
Molecules. 2020 Mar 3;25(5):1128. doi: 10.3390/molecules25051128.
10
Application of computational methods for anticancer drug discovery, design, and optimization.计算方法在抗癌药物发现、设计和优化中的应用。
Bol Med Hosp Infant Mex. 2016 Nov-Dec;73(6):411-423. doi: 10.1016/j.bmhimx.2016.10.006. Epub 2016 Nov 30.
本文引用的文献
1
HyperCys: A Structure- and Sequence-Based Predictor of Hyper-Reactive Druggable Cysteines.HyperCys：基于结构和序列的高反应性可成药半胱氨酸预测器。
Int J Mol Sci. 2023 Mar 22;24(6):5960. doi: 10.3390/ijms24065960.
2
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.羟肟酸和二氟甲基恶二唑类组蛋白去乙酰化酶 6 抑制剂的体外和细胞选择性。
Int J Mol Sci. 2023 Mar 1;24(5):4720. doi: 10.3390/ijms24054720.
3
Insights into the Transport Cycle of LAT1 and Interaction with the Inhibitor JPH203.LAT1 转运周期的研究进展及其与抑制剂 JPH203 的相互作用
Int J Mol Sci. 2023 Feb 17;24(4):4042. doi: 10.3390/ijms24044042.
4
Inhibition of Neutral Sphingomyelinase 2 by Novel Small Molecule Inhibitors Results in Decreased Release of Extracellular Vesicles by Vascular Smooth Muscle Cells and Attenuated Calcification.新型小分子抑制剂抑制中性鞘磷脂酶 2 可减少血管平滑肌细胞释放细胞外囊泡并减轻钙化。
Int J Mol Sci. 2023 Jan 19;24(3):2027. doi: 10.3390/ijms24032027.
5
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development.人工智能和机器学习技术推动现代药物发现和开发。
Int J Mol Sci. 2023 Jan 19;24(3):2026. doi: 10.3390/ijms24032026.
6
XML-CIMT: Explainable Machine Learning (XML) Model for Predicting Chemical-Induced Mitochondrial Toxicity.XML-CIMT：用于预测化学诱导的线粒体毒性的可解释机器学习（XML）模型。
Int J Mol Sci. 2022 Dec 9;23(24):15655. doi: 10.3390/ijms232415655.
7
Discovery of 3-Amino-1-pyrazole-Based Kinase Inhibitors to Illuminate the Understudied PCTAIRE Family.发现基于 3-氨基-1-吡唑的激酶抑制剂，以阐明研究不足的 PCTAIRE 家族。
Int J Mol Sci. 2022 Nov 27;23(23):14834. doi: 10.3390/ijms232314834.
8
MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.基于 MDM2 的蛋白水解靶向嵌合体（PROTACs）：癌症治疗的创新药物策略。
Int J Mol Sci. 2022 Sep 21;23(19):11068. doi: 10.3390/ijms231911068.
9
Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors.喹诺利嗪类化合物作为新型 SARS-CoV-2 进入抑制剂。
Int J Mol Sci. 2022 Aug 25;23(17):9659. doi: 10.3390/ijms23179659.
10
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.吡嗪连接 2-氨基苯甲酰胺的合成、分子对接及作为新型 I 类选择性组蛋白去乙酰化酶（HDAC）抑制剂的生物学特征及其抗白血病活性。
Int J Mol Sci. 2021 Dec 29;23(1):369. doi: 10.3390/ijms23010369.
Zotero 插件